相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer The STIC CTC Randomized Clinical Trial
Francois-Clement Bidard et al.
JAMA ONCOLOGY (2021)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Massimo Cristofanilli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis
Angela Toss et al.
CLINICAL BREAST CANCER (2019)
How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring
Leonie L. Zeune et al.
CYTOMETRY PART A (2018)
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3
Massimo Cristofanilli et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
Marta Bonotto et al.
BREAST (2017)
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Jeffrey B. Smerage et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Francois-Clement Bidard et al.
LANCET ONCOLOGY (2014)
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Marta Bonotto et al.
ONCOLOGIST (2014)
How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials
Belinda E. Kiely et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Building Predictive Models in R Using the caret Package
Max Kuhn
JOURNAL OF STATISTICAL SOFTWARE (2008)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
